We are live on ! Find out more
LUMO

Lumos Pharma, Inc. Common Stock

Delisted

LUMO was delisted on the 11th of December, 2024.

0 hedge funds and large institutions have $0 invested in Lumos Pharma, Inc. Common Stock in 2024 Q4 according to their latest regulatory filings, with 0 funds opening new positions, 0 increasing their positions, 0 reducing their positions, and 28 closing their positions.

New
Increased
Maintained
Reduced
Closed

100% less funds holding

Funds holding: 280 (-28)

100% less capital invested

Capital invested by funds: $8.08M → $0 (-$8.08M)

100% less first-time investments, than exits

New positions opened: 0 | Existing positions closed: 28

Holders
Holders Change
-28
Holders Change %
-100%
% of All Funds
Holding in Top 10
Holding in Top 10 Change
Holding in Top 10 Change %
% of All Funds
New
Increased
Reduced
Closed
28
Calls
Puts
Net Calls
Net Calls Change
Name Holding Trade Value Shares
Change
Change in
Stake
JP Morgan Chase
26
JP Morgan Chase
New York
-$50 -13 Closed
Jones Financial Companies
27
Jones Financial Companies
Missouri
-$16 -4 Closed

LUMO Hedge Fund Activity: Q4 2024 in Review

0 of the 7,592 institutional investors tracked by Wall St. Rank reported a position in Lumos Pharma, Inc. Common Stock (LUMO) for Q4 2024, worth a combined $0 — down 100% from $8.08M a quarter earlier.

Sellers outnumbered buyers: 28 funds closed out of LUMO and 0 opened new positions — a net loss of 28 holders — while 0 trimmed existing stakes and 0 added.

The largest seller was Private Advisor Group, exiting entirely with an estimated $2.88M sold.

  • 0 institutional investors held Lumos Pharma, Inc. Common Stock (LUMO) as of Q4 2024, down from 28 in Q3 2024.
  • Funds reported $0 of Lumos Pharma, Inc. Common Stock stock for Q4 2024, down 100% quarter-over-quarter.
  • 0 funds opened new Lumos Pharma, Inc. Common Stock positions in Q4 2024 and 28 closed out, a net change of -28 holders.
  • The largest Lumos Pharma, Inc. Common Stock seller in Q4 2024 was Private Advisor Group, an estimated $2.88M sold.

Based on aggregated 13F filings for Q4 2024.